Bendamustine combined to donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014.
Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide. Mediterr J Hematol Infect Dis. 2015;7(1):e2015048.
Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2015;7(1):e2015015..
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. J Clin Oncol. 2016.
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer. 2018.
Donor specific anti-HLA antibodies (DSA) in Haploidentical stem cell transplantation with Post Transplant Cyclophosphamide: risk of graft failure, poor graft function and impact on outcomes. Biol Blood Marrow Transplant. 2019..
Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2019.
Peripheral blood hemopoietic stem cell mobilization regimens in POEMS syndrome: a retrospective study at two haematological Italian centres. Biol Blood Marrow Transplant. 2019.
Acute Graft-versus-Host-Disease other than typical targets: between myths and facts. Biol Blood Marrow Transplant. 2020..
Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv. 2020;4(7):1242-1249.
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020;4(1):136-140.
Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4(16):3900-3912.
Feasibility and efficacy of a PK-guided busulfan conditioning regimen for Allogeneic SCT with PTCY as GVHD prophylaxis in adult patients with hematologic malignancies. Transplant Cell Ther. 2021.
Feasibility and Efficacy of CD45RA+ Depleted Donor Lymphocytes Infusion After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Patients With Hematological Malignancies. Transplant Cell Ther. 2021.
Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. Transplant Cell Ther. 2021.
Impact of the addition of antithymocyte globulin to post-transplant cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplant cyclophosphamide alone in acute myeloid leukemia: a retrospective study on behalf of t. Transplant Cell Ther. 2022.